NASDAQ:AGTCApplied Genetic Technologies Stock Price, Forecast & News

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGTC stock has increased by 50.3% and is now trading at $5.77.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Applied Genetic Technologies.

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020.
View our earnings forecast for Applied Genetic Technologies.

Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($0.50) EPS for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.05.
View Applied Genetic Technologies' earnings history.

7 analysts have issued twelve-month target prices for Applied Genetic Technologies' shares. Their forecasts range from $7.50 to $25.00. On average, they anticipate Applied Genetic Technologies' stock price to reach $15.79 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies.

Media stories about AGTC stock have trended positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Applied Genetic Technologies.

Applied Genetic Technologies saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,950,000 shares, an increase of 59.5% from the June 15th total of 1,850,000 shares. Based on an average daily trading volume, of 380,300 shares, the days-to-cover ratio is currently 7.8 days.
View Applied Genetic Technologies' Short Interest.

Some companies that are related to Applied Genetic Technologies include Aerie Pharmaceuticals (AERI), Fusion Pharmaceuticals (FUSN), Proteon Therapeutics (PRTO), MeiraGTx (MGTX), AVITA MED LTD/S (RCEL), Innate Pharma (IPHYF), Innate Pharma (IPHA), Orchard Therapeutics (ORTX), Prevail Therapeutics (PRVL), BIONDVAX PHARMA/S (BVXV), Aptose Biosciences (APTO), Rubius Therapeutics (RUBY), Voyager Therapeutics (VYGR), Brainstorm Cell Therapeutics (BCLI) and Tcr2 Therapeutics (TCRR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD), Agile Therapeutics (AGRX), Cisco Systems (CSCO) and Allena Pharmaceuticals (ALNA).

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Sofinnova Investments Inc. (4.44%), Portolan Capital Management LLC (3.05%), Bank of New York Mellon Corp (0.28%), Russell Investments Group Ltd. (0.24%), Bank of America Corp DE (0.10%) and New York State Common Retirement Fund (0.08%). Company insiders that own Applied Genetic Technologies stock include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski.
View institutional ownership trends for Applied Genetic Technologies.

AGTC stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd..
View insider buying and selling activity for Applied Genetic Technologies.

AGTC stock was acquired by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, Sofinnova Investments Inc., Bank of New York Mellon Corp, New York State Common Retirement Fund, American International Group Inc., Virtu Financial LLC, Bank of Montreal Can, and Bank of America Corp DE. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan, and William Aliski.
View insider buying and selling activity for Applied Genetic Technologies.

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGTC stock can currently be purchased for approximately $5.77.

Applied Genetic Technologies has a market capitalization of $148.66 million and generates $41.69 million in revenue each year. The biotechnology company earns $-2,010,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Applied Genetic Technologies employs 85 workers across the globe.

The official website for Applied Genetic Technologies is www.agtc.com.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.